0001209191-20-052337.txt : 20200929
0001209191-20-052337.hdr.sgml : 20200929
20200929163827
ACCESSION NUMBER: 0001209191-20-052337
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200925
FILED AS OF DATE: 20200929
DATE AS OF CHANGE: 20200929
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thompson Peter A.
CENTRAL INDEX KEY: 0001357522
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39539
FILM NUMBER: 201209312
MAIL ADDRESS:
STREET 1: C/O ANTHERA PHARMACEUTICALS, INC.
STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
FORMER NAME:
FORMER CONFORMED NAME: Thompson Peter A
DATE OF NAME CHANGE: 20060327
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PMV Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001699382
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463218129
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: (609) 642-6664
MAIL ADDRESS:
STREET 1: 8 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-25
0
0001699382
PMV Pharmaceuticals, Inc.
PMVP
0001357522
Thompson Peter A.
C/O PMV PHARMACEUTICALS, INC.
8 CLARKE DRIVE, SUITE 3
CRANBURY
NJ
08512
1
0
1
0
Common Stock
2020-09-25
4
P
0
475000
18.00
A
475000
I
See footnote
Common Stock
2020-09-29
4
C
0
4025076
A
4500076
I
See footnote
Common Stock
2020-09-29
4
C
0
1076891
A
5576967
I
See footnote
Common Stock
2020-09-29
4
C
0
518191
A
6095158
I
See footnote
Common Stock
2020-09-29
4
C
0
380133
A
6475291
I
See footnote
Common Stock
2020-09-29
4
C
0
114039
A
114039
I
See footnote
Common Stock
2020-09-25
4
P
0
475000
18.00
A
475000
I
See footnote
Series A Preferred Stock
2020-09-29
4
C
0
4025076
0.00
D
Common Stock
4025076
0
I
See footnote
Series B Preferred Stock
2020-09-29
4
C
0
1076891
0.00
D
Common Stock
1076891
0
I
See footnote
Series C Preferred Stock
2020-09-29
4
C
0
518191
0.00
D
Common Stock
518191
0
I
See footnote
Series D Preferred Stock
2020-09-29
4
C
0
380133
0.00
D
Common Stock
380133
0
I
See footnote
Series D Preferred Stock
2020-09-29
4
C
0
114039
0.00
D
Common Stock
114039
0
I
See footnote
The shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V.
Each of GP V, OrbiMed Advisors, OrbiMed Genesis GP LLC ("Genesis GP"), OrbiMed Capital LLC ("OrbiMed Capital"), Messrs. Borho and Silverstein, Dr. Gordon, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Person is an employee of OrbiMed Advisors.
The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.
The shares are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). Genesis GP is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis Master Fund and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
The shares are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM.
/s/ David H. Mack, attorney-in-fact
2020-09-29